Detalhe da pesquisa
1.
Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience.
Anticancer Drugs
; 32(1): 88-94, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33332891
2.
Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma.
Eur J Haematol
; 107(2): 246-254, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33934417
3.
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
Eur J Haematol
; 102(5): 389-394, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30719772
4.
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.
Eur J Haematol
; 95(6): 576-82, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25692738
5.
CD200 genotype is associated with clinical outcome of patients with multiple myeloma.
Front Immunol
; 15: 1252445, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38455039
6.
Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.
Front Immunol
; 14: 1158105, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37122695
7.
Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas.
Clin Lymphoma Myeloma Leuk
; 22(8): 635-642, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35610120
8.
The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting.
Cancer Rep (Hoboken)
; 4(4): e1358, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33656801
9.
Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
J Peripher Nerv Syst
; 15(1): 17-25, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20433602
10.
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?
Clin Lymphoma Myeloma Leuk
; 19(9): 585-592.e1, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31255588